Niquitin Mini (Nicotine)

Nicotine in Niquitin Mini binds to nicotinic acetylcholine receptors located in the lining of the mouth. This partial stimulation releases neurotransmitters that lessen the intensity of withdrawal, allowing the user to gradually taper nicotine intake under professional guidance.

The appropriate dose of Niquitin Mini is determined by the prescribing health‑care professional based on the individual’s smoking history, level of dependence, and any co‑existing medical conditions. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

The safety of nicotine replacement therapy, including Niquitin Mini, has not been definitively established in pregnancy or lactation. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their health‑care provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Niquitin Mini delivers nicotine via the oral mucosa, similar to lozenges or gum, but may offer a faster onset of relief compared with transdermal patches. Unlike cigarettes, it provides a controlled dose without combustion products, reducing exposure to harmful tar and carbon monoxide.

Store Niquitin Mini at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability.

Niquitin Mini is placed in the mouth and allowed to dissolve slowly against the oral mucosa. The user should avoid chewing or swallowing the product whole, and should not eat or drink for a few minutes after placement to ensure optimal absorption.

Serious risks, though rare, include allergic reactions such as rash, swelling, or difficulty breathing, as well as cardiovascular events like chest pain, palpitations, or rapid heart rate. Any signs of these reactions require immediate medical attention.

Niquitin Mini should not be used by individuals who are not regular smokers, by those with known hypersensitivity to nicotine or any excipients, and by patients with uncontrolled cardiovascular disease without medical supervision. Pregnant or breastfeeding women should consult a health‑care professional before use.